Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.


Pharmaceutical Technology
pp. s16-s22, s28-s31

27. K. Hipkins, Pharm. Tech. Eur. 2, 157–163 (2007).

28. C. Justice et al., Biotechnol. Adv. 29, 391–401 (2011).

29. A. Sharma, and S.G. Schulman, Wiley InterScience 2, 172–176 (1999).

30. S. Marose, C. Lindemann, and T. Scheper, Biotech. Progress 14, 63–74, (1998).

31. P. Ana Teixeira et al., Wiley InterScience 102, 1108–1116 (2008).

32. P. Ana Teixeira, M. Tiago Duarte, M.J.T. Carrondo, and M. Paula Alves, Biotechnol.Bioeng. 102, 1852–1861 (2011).

33. M. Reinecke and T. Scheper, J. Biotechnol. 17, 145–53 (1997).

34. A.S. Rathore, L. Parr, S. Dermawan, K. Lawson, and Y. Lu, Biotechnol. Prog. 26, 448–57 (2010).

35. A.S. Rathore, R. Wood, A. Sharma, and S. Dermawan, Biotechnol. Bioeng. 101, 1366–1374 (2008).

36. A.S. Rathore, A. Sharma, and D. Chilin, BioPharm Int. 19, 48–57 (2006).

37. M. Tina Larson et al., Biotech. and Bioengin. 77, 553–563 (2002).

38. R.L. Fahrner et al., J. Chromatogr. A. 827, 37–43 (1998).

39. J. Barackman, I.Prado, C. Karunatilake, and K. Furuya, J. Chromatogr. A. 16, 57–64 (2004).

40. C. Bittner, G. Wehnert, and T. Scheper, Biotechnol. Bioeng. 60, 24–35 (1998).

41. V. Camisard et al., Biotechnol. Bioeng. 78, 73–80 (2002).

42. J.S. Guez et al., J. Biotechnol. 111, 335–343 (2004).

43. G. Rudolph et al., Biotechnol. Bioeng. 99, 136–145 (2008).

44. N. Wei et al., Biotechnol. Lett. 29, 373–378 (2007).

45. A. Prediger et al., Chem. Engin. & Tech. 34, 837–840 (2011).

46. C. Buschmüller et al., Eur. J. Pharm. Biopharm. 69, 380–387 (2008).

47. http://www.nature.com/naturephotonics/.

48. M.P. Wagh, Y.H. Sonawane, and O.U. Joshi., Indian J. Pharm. Sci. 71, 235–241 (2009).

49. H. Wu, E.J. Heilweil, A.S, Hussain, and M.A. Khan, J. Pharm. Sci. 97, 970–984 (2008).

50. T. Schmid, Anal. Bioanal. Chem. 384, 1071–1086 (2006).

51. V. Deepak Bageshwar, S. Avinash Pawar, V. Vineeta Khanvilkar, and J. Vilasrao Kadam, Eurasian J. Anal. Chem. 5, 187–203 (2010).

52. T. Schmid et al., Environ. Sci. Technol. 36, 4135–4141 (2002).

53. http://pharma.metrohm.com/pdfdownload/Prosp_Pharma_Analytik_e_web.pdf.

54. W. Chew and P. Sharratt, Anal. Methods 2, 1412–1438 (2010).

55. P. Werle, R. Mücke, and F. Slemr, App. Phys. B: Lasers and Optics 57, 131–139 (1993).

56. S. Armenta, S. Garrigues, M. Gauradia, and P. Rondeau, Anal. Chem. Acta. 545, 99–106 (2005).

57. A.S. Rathore, R. Bhambure, and V. Ghare, Bioanal. Chem. 398, 137–154 (2010).

*This article was previously published in the January 2012 issue of LCGC North America.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here